Biotech & Health Tech
STAT+: Oura’s acquisition of health tech startup raises conflict-of-interest questions for Eli Lilly, experts say
With a new deal announced this week, the relationship between Eli Lilly and a telehealth company that markets GLP-1s is expected to grow more complicated.
With a new deal announced this week, the relationship between Eli Lilly and a telehealth company that markets GLP-1s is expected to grow more complicated.
This is a summary of the story. Read the full article at Stat News (Biotech & Health Tech) ↗